Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa M Younk

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Clinical Chemistry|October 27, 2010
Hypoglycemia and vascular diseaseLisa M Younk, Stephen N Davis
Expert Opinion on Drug Metabolism & Toxicology|March 22, 2012
Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetesLisa M Younk, Stephen N Davis
Expert Opinion on Pharmacotherapy|May 14, 2011
Pramlintide and the treatment of diabetes: a review of the data since its introductionLisa M Younk, Maia Mikeladze, Stephen N Davis
Expert Opinion on Drug Metabolism & Toxicology|April 28, 2011
Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular riskLisa M Younk, Lisa Uhl, Stephen N Davis
Expert Opinion on Drug Metabolism & Toxicology|April 18, 2013
Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitusElizabeth M Lamos, Lisa M Younk, Stephen N Davis
Therapeutics and Clinical Risk Management|March 30, 2016
Concentrated insulins: the new basal insulinsElizabeth M Lamos, Lisa M Younk, Stephen N Davis
Expert Opinion on Investigational Drugs|April 22, 2014
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetesElizabeth M Lamos, Lisa M Younk, Stephen N Davis
Expert Opinion on Drug Safety|June 6, 2014
The cardiovascular effects of insulinLisa M Younk, Elizabeth M Lamos, Stephen N Davis
Expert Opinion on Drug Safety|June 9, 2016
Cardiovascular effects of anti-diabetes drugsLisa M Younk, Elizabeth M Lamos, Stephen N Davis
Expert Review of Endocrinology & Metabolism|February 23, 2011
Exercise-related hypoglycemia in diabetes mellitusLisa M Younk, Maia Mikeladze, Donna Tate, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Clinical Chemistry|October 27, 2010
Hypoglycemia and vascular diseaseLisa M Younk, Stephen N Davis
Expert Opinion on Drug Metabolism & Toxicology|March 22, 2012
Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetesLisa M Younk, Stephen N Davis
Expert Opinion on Pharmacotherapy|May 14, 2011
Pramlintide and the treatment of diabetes: a review of the data since its introductionLisa M Younk, Maia Mikeladze, Stephen N Davis
Expert Opinion on Drug Metabolism & Toxicology|April 28, 2011
Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular riskLisa M Younk, Lisa Uhl, Stephen N Davis
Expert Opinion on Drug Metabolism & Toxicology|April 18, 2013
Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitusElizabeth M Lamos, Lisa M Younk, Stephen N Davis
Therapeutics and Clinical Risk Management|March 30, 2016
Concentrated insulins: the new basal insulinsElizabeth M Lamos, Lisa M Younk, Stephen N Davis
Expert Opinion on Investigational Drugs|April 22, 2014
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetesElizabeth M Lamos, Lisa M Younk, Stephen N Davis
Expert Opinion on Drug Safety|June 6, 2014
The cardiovascular effects of insulinLisa M Younk, Elizabeth M Lamos, Stephen N Davis
Expert Opinion on Drug Safety|June 9, 2016
Cardiovascular effects of anti-diabetes drugsLisa M Younk, Elizabeth M Lamos, Stephen N Davis
Expert Review of Endocrinology & Metabolism|February 23, 2011
Exercise-related hypoglycemia in diabetes mellitusLisa M Younk, Maia Mikeladze, Donna Tate, et al.
Pageof 2